It was developed by the University of Oxford and recommended by WHO. In trials, the R21/Matrix-M jab reduced symptomatic cases by 75% without triggering any safety concerns. WHO approval paves the way for a mass rollout from mid-2024. Doses will cost between $2 and $4. India’s Serum Institute has already made 20 million doses and could scale up to 200 million a year.